Response to Comments: MolDX: Breast Cancer IndexTM (BCI) Gene Expression Test

This document is a response to comments on the MolDX Breast Cancer Index (BCI) gene expression test (DL37794) and records the comment period (06/04/2018–07/19/2018), notice period (01/24/2019–03/10/2019), and that the LCD becomes final on 03/11/2019. The document does not provide clinical indications, limitations, documentation requirements for claims, or frequency limits for the BCI test; further review of the final LCD is required for coverage criteria.

"Policy document records the public comment period for MolDX: Breast Cancer Index (BCI) DL37794 from 2018-06-04 to 2018-07-19, the notice period from 2019-01-24 to 2019-03-10, and that the LCD becom..."

Sign up to see full coverage criteria, indications, and limitations.